Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients

Huimei An; Xiangdong Du; Xingbing Huang; Lingyan Qi; Qiufang Jia; Guangzhong Yin; Chunling Xiao; Xu-Feng Huang; Yuping Ning; Ryan M Cassidy; Li Wang; Jair C. Soares; Xiang Yang Zhang

doi:10.1038/s41398-018-0303-7

journal article Open Access Nov 29, 2018

Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients

Huimei An Xiangdong Du Xingbing Huang Lingyan Qi Qiufang Jia Guangzhong Yin Chunling Xiao Xu-Feng Huang

Yuping Ning Ryan M Cassidy Li Wang

Jair C. Soares

Xiang Yang Zhang

Translational Psychiatry Vol. 8 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/s41398-018-0303-7

Abstract

AbstractAntipsychotic pharmacotherapy is strongly obesogenic and is associated with increased oxidative stress in patients with schizophrenia. However, whether these changes reflect psychopathology, antipsychotic efficacy, or some other factor is not known. Our study aims to investigate the degree of oxidative stress in different BMI categories and to identify clinical symptomatology that may be paired with increased oxidative stress in a schizophrenia population. To this end, we performed a cross-sectional study and recruited 89 long-term inpatients with schizophrenia and collected the following variables: plasma malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), routine biochemical analysis, and psychopathology through the Positive and Negative Syndrome Scale (PANSS). The results indicate that the levels of the lipid peroxidation product, MDA, were significantly higher in the high BMI group than the low (normal) BMI group. As expected, high BMI was associated with an atherogenic lipid profile; however, it was also associated with fewer psychopathological symptoms. Multiple regression analysis found that MDA levels, the PANSS general psychopathology subscore, and triglyceride levels (all p < 0.05) were independent contributors to the BMI in patients. These results suggested that oxidative stress may play an important role in antipsychotic-induced weight gain. Further investigations using the longitudinal design in first-episode schizophrenia patients are needed to explore the beneficial effect of antioxidants on the abnormal lipid metabolism mediated by antipsychotic treatment.

Topics

No keywords indexed for this article. Browse by subject →

References

59

[1]

Allison, D. B. et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am. J. Prev. Med. 36, 341–350 (2009). 10.1016/j.amepre.2008.11.020

[2]

The prevalence, risk factors and clinical correlates of obesity in Chinese patients with schizophrenia

Qiongzhen Li, Xiangdong Du, Yingyang Zhang et al.

Psychiatry Research 2017 10.1016/j.psychres.2016.12.041

[3]

Manu, P. et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr. Scand. 132, 97–108 (2015). 10.1111/acps.12445

[4]

Weiden, P. J., Mackell, J. A. & McDonnell, D. D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res. 66, 51–57 (2004). 10.1016/s0920-9964(02)00498-x

[5]

Castillo-Sanchez, M., Fabregas-Escurriola, M., Berge-Baquero, D., Fernandez-SanMartin, M. & Goday-Arno, A. Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population? Clin. Exp. Hypertens. 39, 441–447 (2017). 10.1080/10641963.2016.1267200

[6]

Excess Early Mortality in Schizophrenia

Thomas Munk Laursen, Merete Nordentoft, Preben Bo Mortensen

Annual Review of Clinical Psychology 2014 10.1146/annurev-clinpsy-032813-153657

[7]

Excess Mortality, Causes of Death and Life Expectancy in 270,770 Patients with Recent Onset of Mental Disorders in Denmark, Finland and Sweden

Merete Nordentoft, Kristian Wahlbeck, Jonas Hällgren et al.

PLoS ONE 2013 10.1371/journal.pone.0055176

[8]

Druss, B. G., Zhao, L., Von Esenwein, S., Morrato, E. H. & Marcus, S. C. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med. Care 49, 599–604 (2011). 10.1097/mlr.0b013e31820bf86e

[9]

McDonald, S. D. et al. What psychological, physical, lifestyle, and knowledge factors are associated with excess or inadequate weight gain during pregnancy? A cross-sectional survey. J. Obstet. Gynaecol. Can. 35, 1071–1082 (2013). 10.1016/s1701-2163(15)30757-x

[10]

Berg, D., Youdim, M. B. & Riederer, P. Redox imbalance. Cell Tissue Res. 318, 201–213 (2004). 10.1007/s00441-004-0976-5

[11]

Kohen, R. & Nyska, A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol. 30, 620–650 (2002). 10.1080/01926230290166724

[12]

Steullet, P. et al. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol. Psychiatry 22, 936–943 (2017). 10.1038/mp.2017.47

[13]

Yao, J. K. & Reddy, R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid. Redox Signal. 15, 1999–2002 (2011). 10.1089/ars.2010.3646

[14]

Bitanihirwe, B. K. & Woo, T. U. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 35, 878–893 (2011). 10.1016/j.neubiorev.2010.10.008

[15]

Zhang, Y., Catts, V. S. Shannon Weickert C. Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia. Aust. N. Z. J. Psychiatry 52, 690–698 (2018). 10.1177/0004867417728805

[16]

Nucifora, L. G. et al. Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. Transl. Psychiatry 7, e1215 (2017). 10.1038/tp.2017.178

[17]

Morera-Fumero, A. L., Diaz-Mesa, E., Abreu-Gonzalez, P., Fernandez-Lopez, L. & Cejas-Mendez, M. D. Low levels of serum total antioxidant capacity and presence at admission and absence at discharge of a day/night change as a marker of acute paranoid schizophrenia relapse. Psychiatry Res. 249, 200–205 (2017). 10.1016/j.psychres.2017.01.043

[18]

Raffa, M. et al. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1178–1183 (2009). 10.1016/j.pnpbp.2009.06.018

[19]

Gunes, M. et al. Evaluation of paraoxonase, arylesterase and malondialdehyde levels in schizophrenia patients taking typical, atypical and combined antipsychotic treatment. Clin. Psychopharmacol. Neurosci. 14, 345–350 (2016). 10.9758/cpn.2016.14.4.345

[20]

Devanarayanan, S., Nandeesha, H., Kattimani, S. & Sarkar, S. Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study. Clin. Chem. Lab. Med. 54, 447–452 (2016). 10.1515/cclm-2015-0212

[21]

Al-Chalabi, B. M., Thanoon, I. A. & Ahmed, F. A. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 59, 8–11 (2009). 10.1159/000202823

[22]

Zhang, X. Y. et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 81, 291–300 (2006). 10.1016/j.schres.2005.10.011

[23]

Li, X. F. et al. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1064–1067 (2011). 10.1016/j.pnpbp.2011.03.001

[24]

Yao, J. K., Reddy, R., McElhinny, L. G. & van Kammen, D. P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 32, 1–8 (1998). 10.1016/s0920-9964(98)00030-9

[25]

Sadowska-Bartosz, I. et al. Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia. Schizophr. Res. 176, 245–251 (2016). 10.1016/j.schres.2016.07.010

[26]

Tsai, M. C., Liou, C. W., Lin, T. K., Lin, I. M. & Huang, T. L. Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs. Psychiatry Res. 209, 284–290 (2013). 10.1016/j.psychres.2013.01.023

[27]

Zhang, X. Y. et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 62, 1928–1934 (2012). 10.1016/j.neuropharm.2011.12.014

[28]

Increased oxidative stress in obesity and its impact on metabolic syndrome

Shigetada Furukawa, Takuya Fujita, Michio Shimabukuro et al.

Journal of Clinical Investigation 2004 10.1172/jci21625

[29]

Vincent, H. K., Innes, K. E. & Vincent, K. R. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes. Metab. 9, 813–839 (2007). 10.1111/j.1463-1326.2007.00692.x

[30]

Chrysohoou, C. et al. The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. Nutr. Metab. Cardiovasc. Dis. 17, 590–597 (2007). 10.1016/j.numecd.2006.05.007

[31]

Sankhla, M. et al. Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin. Lab. 58, 385–392 (2012).

[32]

Vincent, H. K. & Taylor, A. G. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int. J. Obes. (Lond.). 30, 400–418 (2006). 10.1038/sj.ijo.0803177

[33]

Manna, P. & Jain, S. K. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab. Syndr. Relat. Disord. 13, 423–444 (2015). 10.1089/met.2015.0095

[34]

Marseglia, L. et al. Oxidative stress in obesity: a critical component in human diseases. Int. J. Mol. Sci. 16, 378–400 (2014). 10.3390/ijms16010378

[35]

Le Lay, S., Simard, G., Martinez, M. C. & Andriantsitohaina, R. Oxidative stress and metabolic pathologies: from an adipocentric point of view. Oxid. Med. Cell Longev. 2014, 908539 (2014). 10.1155/2014/908539

[36]

Ji, C. Y. & Chen, T. J., Working Group on Obesity in China (WGOC). Empirical changes in the prevalence of overweight and obesity among Chinese students from 1985 to 2010 and corresponding preventive strategies. Biomed. Environ. Sci. 26, 1–12 (2013).

[37]

Yagi, K. Lipid peroxides and related radicals in clinical medicine. Adv. Exp. Med. Biol. 366, 1–15 (1994). 10.1007/978-1-4615-1833-4_1

[38]

Oyanagui, Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal. Biochem. 142, 290–296 (1984). 10.1016/0003-2697(84)90467-6

[39]

Paglia, D. E. & Valentine, W. N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70, 158–169 (1967).

[40]

Aebi, H. Catalase in vitro. Methods Enzymol. 105, 121–126 (1984). 10.1016/s0076-6879(84)05016-3

[41]

Lee, E. E. et al. Elevated plasma F2-isoprostane levels in schizophrenia. Schizophr. Res. 176, 320–326 (2016). 10.1016/j.schres.2016.06.011

[42]

Wang, C. H., Wang, C. C., Huang, H. C. & Wei, Y. H. Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes. Febs. J. 280, 1039–1050 (2013). 10.1111/febs.12096

[43]

Das, P., Biswas, S., Mukherjee, S. & Bandyopadhyay, S. K. Association of oxidative stress and obesity with insulin resistance in type 2 diabetes mellitus. Mymensingh. Med. J. 25, 148–152 (2016).

[44]

Picu A., et al. Markers of oxidative stress and antioxidant defense in Romanian patients with type 2 diabetes mellitus and obesity. Molecules 22, E714 (2017). 10.3390/molecules22050714

[45]

Zaki, M. E., El-Bassyouni, H., Kamal, S., El-Gammal, M. & Youness, E. Association of serum paraoxonase enzyme activity and oxidative stress markers with dyslipidemia in obese adolescents. Indian J. Endocrinol. Metab. 18, 340–344 (2014). 10.4103/2230-8210.131173

[46]

Atmaca, M., Tezcan, E., Kuloglu, M., Ustundag, B. & Kirtas, O. The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin. Neurosci. 59, 652–656 (2005). 10.1111/j.1440-1819.2005.01432.x

[47]

Zhou, D. et al. The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. Chin. Med. J. (Engl.). 112, 1093–1096 (1999).

[48]

Meltzer, H. Y., Perry, E. & Jayathilake, K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr. Res. 59, 19–27 (2003). 10.1016/s0920-9964(01)00326-7

[49]

Ascher-Svanum, H., Stensland, M. D., Kinon, B. J. & Tollefson, G. D. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J. Psychopharmacol. 19(6 Suppl), 110–117 (2005). 10.1177/0269881105058978

[50]

Hui, L. et al. Obesity correlates with fewer symptoms in schizophrenia treated with long-term clozapine: gender difference. Psychiatry Res. 225, 741–742 (2015). 10.1016/j.psychres.2014.12.035

Showing 50 of 59 references

Cited By

56

Neuroprotective effects of alpha-pinene against behavioral deficits in ketamine-induced mice model of schizophrenia: Focusing on oxidative stress status

Akbar Hajizadeh Moghaddam, Fatemeh Malekzadeh Estalkhi · 2024

IBRO Neuroscience Reports

Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders

Alex J. Murray, Jack C. Rogers · 2021

Frontiers in Psychiatry

Metrics

56

Citations

59

References

Details

Published: Nov 29, 2018
Vol/Issue: 8(1)
License: View

Authors

Chinese Academy of Sciences

Funding

National Natural Science Foundation of China Award: 81371477

Natural Science Foundation of Beijing Municipality Award: 7182074

Beijing Municipal Excellent Talents Foundation

Beijing Science and Technology Foundation

Cite This Article

Huimei An, Xiangdong Du, Xingbing Huang, et al. (2018). Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients. Translational Psychiatry, 8(1). https://doi.org/10.1038/s41398-018-0303-7

Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients

You May Also Like